Literature DB >> 15669791

Tuberculum sellae meningiomas.

John H Chi1, Michael W McDermott.   

Abstract

Tuberculum sellae meningiomas are a classic tumor of the anterior fossa that present in patients with gradual visual deterioration secondary to optic apparatus compression. If untreated, complete blindness can occur. Treatment involves tumor removal and decompression of the optic chiasm via several operative approaches. Gross-total resection (Simpson Grade I or II) is the goal of treatment and can usually be accomplished safely. Special excision-related considerations include appreciation of arachnoid planes separating the tumor from neural tissue, adequate drilling of osseous elements for optimal exposure, and intraoperative preservation of the vascular supply to the optic apparatus. The authors reviewed their experience at the University of California, San Francisco, in cases of tuberculum sellae meningiomas treated between 1992 and 2002. In most patients, improvement of vision can be achieved with minimal postoperative complications and morbidity.

Entities:  

Mesh:

Year:  2003        PMID: 15669791     DOI: 10.3171/foc.2003.14.6.6

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  12 in total

1.  The contralateral subfrontal approach can simplify surgery and provide favorable visual outcome in tuberculum sellae meningiomas.

Authors:  Woo-Youl Jang; Shin Jung; Tae-Young Jung; Kyung-Sub Moon; In-Young Kim
Journal:  Neurosurg Rev       Date:  2012-06-06       Impact factor: 3.042

2.  Optic nerve potentials and cortical potentials after stimulation of the anterior visual pathway during neurosurgery.

Authors:  Mitja Benedičič; Roman Bošnjak
Journal:  Doc Ophthalmol       Date:  2011-03-16       Impact factor: 2.379

Review 3.  Endoscopic surgery for tuberculum sellae meningiomas: a systematic review and meta-analysis.

Authors:  Aaron J Clark; Arman Jahangiri; Roxanna M Garcia; Jonathan R George; Michael E Sughrue; Michael W McDermott; Ivan H El-Sayed; Manish K Aghi
Journal:  Neurosurg Rev       Date:  2013-04-09       Impact factor: 3.042

4.  Supraorbital keyhole approach for removal of midline anterior cranial fossa meningiomas: a series of 20 consecutive cases.

Authors:  Stefano Telera; Carmine Maria Carapella; Fabrizio Caroli; Francesco Crispo; Giovanni Cristalli; Laura Raus; Isabella Sperduti; Alfredo Pompili
Journal:  Neurosurg Rev       Date:  2011-07-29       Impact factor: 3.042

5.  Endoscopic resection of tuberculum sellae meningiomas.

Authors:  Nisha Gadgil; Jonathan G Thomas; Masayoshi Takashima; Daniel Yoshor
Journal:  J Neurol Surg B Skull Base       Date:  2013-04-12

6.  Characteristic of optic canal invasion in 31 consecutive cases with tuberculum sellae meningioma.

Authors:  Pree Nimmannitya; Takeo Goto; Yuzo Terakawa; Hidetoshi Sato; Toshiyuki Kawashima; Hiroki Morisako; Kenji Ohata
Journal:  Neurosurg Rev       Date:  2016-04-27       Impact factor: 3.042

7.  Pterional approach versus unilateral frontal approach on tuberculum sellae meningioma: Single centre experiences.

Authors:  Muhammad Zafrullah Arifin; Ignatius Mardjono; Roland Sidabutar; Beny Atmadja Wirjomartani; Ahmad Faried
Journal:  Asian J Neurosurg       Date:  2012-01

8.  Tuberculum sellae meningiomas: A series of 41 cases; surgical and ophthalmological outcomes with proposal of a new prognostic scoring system.

Authors:  Arun Palani; Manas K Panigrahi; Anirudh K Purohit
Journal:  J Neurosci Rural Pract       Date:  2012-09

9.  Endoscopic Endonasal Transsphenoidal Approach for Resection of Tuberculum Sella and Planum Sphenoidale Meningiomas: A Snapshot of Our Institutional Experience.

Authors:  Md Al Amin Salek; Md Hasnain Faisal; Md Abdul Hye Manik; Ahmed-Ul-Mursalin Choudhury; Rukun Uddin Chowdhury; Md Aminul Islam
Journal:  Asian J Neurosurg       Date:  2020-02-25

10.  A systematic review of the surgical anatomy of the orbital apex.

Authors:  Ӧ Engin; G F J P M Adriaensen; F W A Hoefnagels; P Saeed
Journal:  Surg Radiol Anat       Date:  2020-10-31       Impact factor: 1.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.